Clare Arnott

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2093672/publications.pdf

Version: 2024-02-01

61 papers	2,693 citations	346980 22 h-index	223390 49 g-index
61 all docs	61 docs citations	61 times ranked	3859 citing authors

#	Article	IF	Citations
1	Effects of canagliflozin on myocardial infarction: a post hoc analysis of the CANVAS programme and CREDENCE trial. Cardiovascular Research, 2022, 118, 1103-1114.	1.8	13
2	The impact of canagliflozin on the risk of neuropathy events: A post-hoc exploratory analysis of the CREDENCE trial. Diabetes and Metabolism, 2022, 48, 101331.	1.4	5
3	Cardiovascular and renal outcomes with canagliflozin in patients with peripheral arterial disease: Data from the <scp>CANVAS</scp> Program and <scp>CREDENCE</scp> trial. Diabetes, Obesity and Metabolism, 2022, 24, 1072-1083.	2.2	20
4	Colchicine in Cardiovascular Disease: In-Depth Review.. Circulation, 2022, 145, 61-78.	1.6	37
5	Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials. Circulation, 2022, 145, 1460-1470.	1.6	97
6	Canagliflozin and atrial fibrillation in type 2 diabetes mellitus: A secondary analysis from the CANVAS Program and CREDENCE trial and metaâ€analysis. Diabetes, Obesity and Metabolism, 2022, 24, 1927-1938.	2.2	10
7	Risk Factors for Fracture in Patients with Coexisting Chronic Kidney Disease and Type 2 Diabetes: An Observational Analysis from the CREDENCE Trial. Journal of Diabetes Research, 2022, 2022, 1-12.	1.0	3
8	Mechanisms of action of the sodiumâ€glucose cotransporterâ€2 (<scp>SGLT2)</scp> inhibitor canagliflozin on tubular inflammation and damage: A post hoc mediation analysis of the <scp>CANVAS</scp> trial. Diabetes, Obesity and Metabolism, 2022, 24, 1950-1956.	2.2	11
9	Optimising mothersâ€™ health behaviour after hypertensive disorders of pregnancy: a qualitative study of a postnatal intervention. BMC Public Health, 2022, 22, .	1.2	7
10	Cardiovascular Disease in Women: From Pathophysiology to Novel and Emerging Risk Factors. Heart Lung and Circulation, 2021, 30, 9-17.	0.2	45
11	An exploration of the heterogeneity in effects of SGLT2 inhibition on cardiovascular and all-cause mortality in the EMPA-REG OUTCOME, CANVAS Program, DECLARE-TIMI 58, and CREDENCE trials. International Journal of Cardiology, 2021, 324, 165-172.	0.8	6
12	<scp>Sodiumâ€glucose coâ€transporterâ€2</scp> inhibitors with and without metformin: A metaâ€analysis of cardiovascular, kidney and mortality outcomes. Diabetes, Obesity and Metabolism, 2021, 23, 382-390.	2.2	40
13	Sodiumâ€glucose coâ€transporterâ€2 inhibition and ocular outcomes in patients with type 2 diabetes: A systematic review and metaâ€analysis. Diabetes, Obesity and Metabolism, 2021, 23, 252-257.	2.2	12
14	Cardiovascular and renal outcomes with canagliflozin according to baseline diuretic use: a post hoc analysis from the CANVAS Program. ESC Heart Failure, 2021, 8, 1482-1493.	1.4	16
15	Mortality in STEMI patients without standard modifiable risk factors: a sex-disaggregated analysis of SWEDEHEART registry data. Lancet, The, 2021, 397, 1085-1094.	6.3	146
16	Effects of a reduced-sodium added-potassium salt substitute on blood pressure in rural Indian hypertensive patients: a randomized, double-blind, controlled trial. American Journal of Clinical Nutrition, 2021, 114, 185-193.	2.2	36
17	The longâ€term cardiovascular impact of hypertension in pregnancy â€“ A missed opportunity. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2021, 61, 474-477.	0.4	8
18	The effects of canagliflozin on heart failure and cardiovascular death by baseline participant characteristics: Analysis of the <scp>CREDENCE</scp> trial. Diabetes, Obesity and Metabolism, 2021, 23, 1652-1659.	2.2	6

#	Article	IF	Citations
19	Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease. Circulation, 2021, 143, 1735-1749.	1.6	60
20	Why Are We Forgetting Patients With Peripheral Arterial Disease?. Heart Lung and Circulation, 2021, 30, 939-942.	0.2	1
21	Guideline-Directed Medical Therapy in Females with Heart Failure with Reduced Ejection Fraction. Current Heart Failure Reports, 2021, 18, 284-289.	1.3	10
22	Association of Baseline Diuretic Use With Cardiovascular Outcomes in Patients With Heart Failure With Preserved Ejection Fraction: A Secondary Analysis From TOPCAT. Journal of Cardiac Failure, 2021, 27, 816-818.	0.7	0
23	Sex Disparities in Sudden Cardiac Death. Circulation: Arrhythmia and Electrophysiology, 2021, 14, e009834.	2.1	14
24	Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial. European Heart Journal, 2021, 42, 4891-4901.	1.0	80
25	Effects of canagliflozin compared with placebo on major adverse cardiovascular and kidney events in patient groups with different baseline levels of HbA1c, disease duration and treatment intensity: results from the CANVAS Program. Diabetologia, 2021, 64, 2402-2414.	2.9	6
26	Effects of the SGLT2 inhibitor canagliflozin on plasma biomarkers TNFR-1, TNFR-2 and KIM-1 in the CANVAS trial. Diabetologia, 2021, 64, 2147-2158.	2.9	45
27	Procedural Volumes in the Era of COVID: The Risk Versus Benefit Trade-Off. Heart Lung and Circulation, 2021, 30, 1430-1432.	0.2	2
28	The Role of Sodium Glucose Cotransporter-2 Inhibitors in Atherosclerotic Cardiovascular Disease: A Narrative Review of Potential Mechanisms. Cells, 2021, 10, 2699.	1.8	7
29	Heart Failure with Reduced Ejection Fractionâ€"Does Sex Matter?. Current Heart Failure Reports, 2021, 18, 345-352.	1.3	15
30	Association Between Circulating GDFâ€15 and Cardioâ€Renal Outcomes and Effect of Canagliflozin: Results From the CANVAS Trial. Journal of the American Heart Association, 2021, 10, e021661.	1.6	16
31	Women and Cardiovascular Disease: Pregnancy, the Forgotten Risk Factor. Heart Lung and Circulation, 2020, 29, 662-667.	0.2	17
32	Rationale, design, and baseline characteristics of the Salt Substitute in India Study (SSiIS): The protocol for a doubleâ€blinded, randomizedâ€controlled trial. Journal of Clinical Hypertension, 2020, 22, 1504-1512.	1.0	11
33	Comparative Efficacy and Safety of BP-Lowering Pharmacotherapy in Patients Undergoing Maintenance Dialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 1129-1138.	2.2	5
34	Blood pressure postpartum (BP2) RCT protocol: Follow-up and lifestyle behaviour change strategies in the first 12Âmonths after hypertensive pregnancy. Pregnancy Hypertension, 2020, 22, 1-6.	0.6	16
35	Assessing knowledge of healthcare providers concerning cardiovascular risk after hypertensive disorders of pregnancy: an Australian national survey. BMC Pregnancy and Childbirth, 2020, 20, 717.	0.9	13
36	Prognostic Value of Secreted Frizzled-Related Protein 5 in Heart Failure Patients With and Without Type 2 Diabetes Mellitus. Circulation: Heart Failure, 2020, 13, e007054.	1.6	46

#	Article	IF	Citations
37	Prognosis of unrecognised myocardial infarction determined by electrocardiography or cardiac magnetic resonance imaging: systematic review and meta-analysis. BMJ, The, 2020, 369, m1184.	3.0	43
38	Maternal cardiovascular risk after hypertensive disorder of pregnancy. Heart, 2020, 106, 1927-1933.	1.2	45
39	Mediators of the effects of canagliflozin on kidney protection in patients with type 2 diabetes. Kidney International, 2020, 98, 769-777.	2.6	69
40	The effect of canagliflozin on amputation risk in the <scp>CANVAS</scp> program and the <scp>CREDENCE</scp> trial. Diabetes, Obesity and Metabolism, 2020, 22, 1753-1766.	2.2	31
41	The effects of combination canagliflozin and glucagon-like peptide-1 receptor agonist therapy on intermediate markers of cardiovascular risk in the CANVAS program. International Journal of Cardiology, 2020, 318, 126-129.	0.8	18
42	Sex Differences in Primary and Secondary Prevention of Cardiovascular Disease in China. Circulation, 2020, 141, 530-539.	1.6	62
43	Sodiumâ€Glucose Cotransporter 2 Inhibition for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Metaâ€Analysis. Journal of the American Heart Association, 2020, 9, e014908.	1.6	161
44	A Novel Cardioprotective Therapy That Also Improves Glycemia. JAMA - Journal of the American Medical Association, 2020, 323, 1349.	3.8	1
45	Do GLP-1 Receptor Agonists Care if You Have Heart Failure?. Circulation, 2019, 140, 1623-1625.	1.6	1
46	Colchicine as a Novel Therapy for Suppressing Chemokine Production in Patients With an Acute Coronary Syndrome: A Pilot Study. Clinical Therapeutics, 2019, 41, 2172-2181.	1.1	33
47	SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes and Endocrinology,the, 2019, 7, 845-854.	5.5	595
48	Tackling Disparities in Heart Care and Disease Outcomes in Women: Insights and Highlights From the Women and Heart Disease Forum. Heart Lung and Circulation, 2019, 28, 1449-1451.	0.2	1
49	A Systematic Review of Vascular Structure and Function in Pre-eclampsia: Non-invasive Assessment and Mechanistic Links. Frontiers in Cardiovascular Medicine, 2019, 6, 166.	1.1	36
50	Sex differences in heart failure. European Heart Journal, 2019, 40, 3859-3868c.	1.0	406
51	The Echocardiographic Characteristics and Prognostic Significance of Pericardial Effusions in Eisenmenger Syndrome. Heart Lung and Circulation, 2018, 27, 394-396.	0.2	1
52	Colchicine Therapy and Plaque Stabilization in Patients With AcuteÂCoronary Syndrome. JACC: Cardiovascular Imaging, 2018, 11, 305-316.	2.3	188
53	Pulmonary vasodilator therapy is associated with greater survival in Eisenmenger syndrome. Heart, 2018, 104, 732-737.	1.2	19
54	Quantifying right atrial filling and emptying: A 4Dâ€flow MRI study. Journal of Magnetic Resonance Imaging, 2017, 45, 1046-1054.	1.9	10

#	Article	IF	Citations
55	Survival outcomes in severe congenital versus non-congenital pulmonary hypertension. Heart Asia, 2016, 8, 3-7.	1.1	6
56	The Vascular Endothelial Growth Factor Inhibitors Ranibizumab and Aflibercept Markedly Increase Expression of Atherosclerosis-Associated Inflammatory Mediators on Vascular Endothelial Cells. PLoS ONE, 2016, 11, e0150688.	1.1	24
57	Subtle increases in heart size persist into adulthood in growth restricted babies: the Cardiovascular Risk in Young Finns Study. Open Heart, 2015, 2, e000265.	0.9	34
58	Pulmonary Vein Isolation Compared to Rate Control in Patients with Atrial Fibrillation: A Systematic Review and Meta-analysis. Heart Lung and Circulation, 2015, 24, 744-752.	0.2	8
59	Paradoxical Cardiac and Cerebral Arterial Gas Embolus During Percutaneous Lead Extraction in a Patient with a Patent Foramen Ovale. Heart Lung and Circulation, 2015, 24, e14-e17.	0.2	7
60	Characterisation of novel cytokines in human atherosclerotic plaque. International Journal of Cardiology, 2014, 176, 1167-1169.	0.8	4
61	A Case of ST Elevation Myocardial Infarction Secondary to Heparin-induced Thrombocytopaenia with Thrombosis. Heart Lung and Circulation, 2012, 21, 841-843.	0.2	8